Xin Hui Chan
Xin Hui Chan
BMBCh MA MSc DPhil MRCP DTM&H DipRCPath
NIHR Academic Clinical Lecturer in Infectious Diseases
- Honorary Specialty Registrar in Infectious Diseases and General Internal Medicine
CLINICAL THERAPEUTICS FOR EMERGING INFECTIOUS DISEASES
Dr Xin Hui Chan is an NIHR Academic Clinical Lecturer in Infectious Diseases at the University of Oxford and an Honorary Specialty Registrar in Infectious Diseases and General Internal Medicine at Oxford University Hospitals. Her current research focuses on accelerating the development of clinical therapeutics for high-threat and emerging infectious diseases. She is part of Prof Sir Peter Horby’s group at the Pandemic Sciences Institute.
Xin Hui trained in medicine, infectious diseases, and tropical medicine in Oxford, London (LSHTM & University College London Hospitals), and Southeast Asia with further experience in North America (US National Institutes of Health), sub-Saharan Africa (MRC Unit The Gambia), and Southeastern Europe.
Her UK MRC-funded DPhil with Prof Sir Nick White at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) was a global evidence review of the cardiovascular safety of antimalarial medicines to optimise their development and deployment in collaboration with the WHO Global Malaria Programme. She was the WHO technical resource person and rapporteur of the WHO Evidence Review Group on the Cardiotoxicity of Antimalarial Medicines.
Chest radiograph classification and severity of suspected COVID-19 by different radiologist groups and attending clinicians: multi-reader, multi-case study
Nair A. et al, (2022), European Radiology
Cardiovascular Concentration‐Effect Relationships of Amodiaquine and its Metabolite Desethylamodiaquine: Clinical and Pre‐clinical Studies
Chan XHS. et al, (2022), British Journal of Clinical Pharmacology
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Abani O. et al, (2022), The Lancet, 400, 359 - 368
Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality.
Chan XHS. et al, (2022), The Journal of hospital infection, 124, 37 - 46
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Abani O. et al, (2022), The Lancet, 399, 665 - 676